CBDMD INC (YCBD) Fundamental Analysis & Valuation

NYSEARCA:YCBD • US12482W4087

Current stock price

0.9475 USD
-0.02 (-2.32%)
Last:

This YCBD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. YCBD Profitability Analysis

1.1 Basic Checks

  • In the past year YCBD has reported negative net income.
  • YCBD had a negative operating cash flow in the past year.
  • YCBD had negative earnings in each of the past 5 years.
  • YCBD had a negative operating cash flow in each of the past 5 years.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of YCBD (-31.53%) is comparable to the rest of the industry.
  • YCBD has a Return On Equity (-41.24%) which is in line with its industry peers.
Industry RankSector Rank
ROA -31.53%
ROE -41.24%
ROIC N/A
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

1.3 Margins

  • With a decent Gross Margin value of 60.59%, YCBD is doing good in the industry, outperforming 69.11% of the companies in the same industry.
  • In the last couple of years the Gross Margin of YCBD has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for YCBD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. YCBD Health Analysis

2.1 Basic Checks

  • YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • YCBD has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for YCBD has been increased compared to 5 years ago.
  • There is no outstanding debt for YCBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -17.65, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -17.65, YCBD is doing worse than 83.25% of the companies in the same industry.
  • There is no outstanding debt for YCBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.65
ROIC/WACCN/A
WACC9.5%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • A Current Ratio of 2.94 indicates that YCBD has no problem at all paying its short term obligations.
  • YCBD has a Current ratio (2.94) which is comparable to the rest of the industry.
  • YCBD has a Quick Ratio of 1.87. This is a normal value and indicates that YCBD is financially healthy and should not expect problems in meeting its short term obligations.
  • YCBD has a worse Quick ratio (1.87) than 60.73% of its industry peers.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 1.87
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. YCBD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 77.34% over the past year.
  • YCBD shows a decrease in Revenue. In the last year, the revenue decreased by -0.66%.
  • Measured over the past years, YCBD shows a very negative growth in Revenue. The Revenue has been decreasing by -14.45% on average per year.
EPS 1Y (TTM)77.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%-1.89%

3.2 Future

  • Based on estimates for the next years, YCBD will show a very strong growth in Earnings Per Share. The EPS will grow by 40.80% on average per year.
  • The Revenue is expected to grow by 8.78% on average over the next years. This is quite good.
EPS Next Y96.47%
EPS Next 2Y40.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.6%
Revenue Next 2Y8.78%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

Find the best growth stocksShow best growing peers

1

4. YCBD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for YCBD. In the last year negative earnings were reported.
  • Also next year YCBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • YCBD's earnings are expected to grow with 40.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.8%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. YCBD Dividend Analysis

5.1 Amount

  • YCBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

YCBD Fundamentals: All Metrics, Ratios and Statistics

CBDMD INC

NYSEARCA:YCBD (4/28/2026, 3:07:52 PM)

0.9475

-0.02 (-2.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-17
Earnings (Next)05-13
Inst Owners7.66%
Inst Owner Change0%
Ins Owners6.43%
Ins Owner Change31.12%
Market Cap9.95M
Revenue(TTM)19.09M
Net Income(TTM)-3.71M
Analysts82.86
Price Target2.04 (115.3%)
Short Float %3.44%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-51.73%
Min EPS beat(2)-138.09%
Max EPS beat(2)34.64%
EPS beat(4)1
Avg EPS beat(4)-262.32%
Min EPS beat(4)-929.41%
Max EPS beat(4)34.64%
EPS beat(8)4
Avg EPS beat(8)-108.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.17%
Min Revenue beat(2)-1.58%
Max Revenue beat(2)1.25%
Revenue beat(4)1
Avg Revenue beat(4)-6.15%
Min Revenue beat(4)-14.83%
Max Revenue beat(4)1.25%
Revenue beat(8)2
Avg Revenue beat(8)-6.58%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)28.57%
EPS NY rev (1m)0%
EPS NY rev (3m)36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.52
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.41
EV/EBITDA N/A
EPS(TTM)-2.32
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.82
BVpS0.86
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -31.53%
ROE -41.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.59%
FCFM N/A
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
F-Score4
Asset Turnover1.62
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.2%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.94
Quick Ratio 1.87
Altman-Z -17.65
F-Score4
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)19.37%
Cap/Depr(5y)25.83%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.73%
EPS Next Y96.47%
EPS Next 2Y40.8%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.66%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%-1.89%
Revenue Next Year10.6%
Revenue Next 2Y8.78%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.08%
OCF growth 3YN/A
OCF growth 5YN/A

CBDMD INC / YCBD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CBDMD INC (YCBD) stock?

ChartMill assigns a fundamental rating of 3 / 10 to YCBD.


What is the valuation status of CBDMD INC (YCBD) stock?

ChartMill assigns a valuation rating of 1 / 10 to CBDMD INC (YCBD). This can be considered as Overvalued.


Can you provide the profitability details for CBDMD INC?

CBDMD INC (YCBD) has a profitability rating of 1 / 10.


Can you provide the financial health for YCBD stock?

The financial health rating of CBDMD INC (YCBD) is 5 / 10.


Is the dividend of CBDMD INC sustainable?

The dividend rating of CBDMD INC (YCBD) is 0 / 10 and the dividend payout ratio is 0%.